Author(s): Jin YJ, Nah SY, Lee JW, Lee JI, Jeong S,
Abstract Share this page
Abstract BACKGROUND & AIMS: More information is needed on use of Primovist-enhanced magnetic resonance imaging (MRI) during initial staging analysis of patients with hepatocellular carcinoma (HCC) who are candidates for treatment with liver dynamic computed tomography (CT). METHODS: We studied 104 patients who were initially diagnosed as Barcelona Clinic Liver Cancer (BCLC) stage 0 or A, without any other suspicious intrahepatic lesions, by liver dynamic CT from December 2009 to May 2012 at Inha University Hospital in Korea. We evaluated whether an addition of Primovist-enhanced MRI examination affected determination of BCLC stage, compared with liver dynamic CT. RESULTS: On the basis of CT analysis, the median tumor size was 2.3 cm, and 98 patients had HCCs that met the Milan criteria (94.2\%). All 104 patients (100\%) had nodular type HCC. Abnormal intrahepatic findings were detected by Primovist-enhanced MRI in 41 patients (39.4\%). Eighteen patients (17.3\%) had new HCCs, but 6 patients who were initially of BCLC stage A remained at this stage, despite increases in tumor numbers. Of the 104 patients, 31 (29.8\%) and 73 (70.2\%) had BCLC stage 0 and A HCC before Primovist-enhanced MRI, respectively, and 26 (25.0\%), 71 (68.3\%), and 7 (6.7\%) patients had BCLC stages 0, A, and B HCC after Primovist-enhanced MRI, respectively. In 12 of the 104 patients (11.5\%), BCLC stage changed from 0 to A (5/31, 16.1\%) or from A to B (7/73, 9.6\%). CONCLUSIONS: Primovist-enhanced MRI can provide additional information that can lead to the detection of new intrahepatic HCC lesions during initial staging analyses of patients with BCLC stage 0 or A HCC by liver dynamic CT, despite the absence of other suspicious liver lesions. Copyright © 2013 AGA Institute. Published by Elsevier Inc. All rights reserved.
This article was published in Clin Gastroenterol Hepatol
and referenced in OMICS Journal of Radiology